List of Xyosted (autoinjector) drug patents

Xyosted (Autoinjector) is owned by Antares Pharma Inc.

Xyosted (Autoinjector) contains Testosterone Enanthate.

Xyosted (Autoinjector) has a total of 21 drug patents out of which 0 drug patents have expired.

Xyosted (Autoinjector) was authorised for market use on 28 September, 2018.

Xyosted (Autoinjector) is available in solution;subcutaneous dosage forms.

Xyosted (Autoinjector) can be used as method of administering testosterone enanthate subcutaneously.

The generics of Xyosted (Autoinjector) are possible to be released after 30 August, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8562564 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US11446441 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(2 years from now)

US9533102 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9180259 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9629959 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US10478560 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(2 years from now)

US8021335 ANTARES PHARMA INC Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US11497753 ANTARES PHARMA INC Hazardous agent injection system
Mar, 2030

(7 years from now)

US10279131 ANTARES PHARMA INC Injection device with cammed RAM assembly
Jul, 2031

(8 years from now)

US11446440 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

US10357609 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Aug, 2031

(8 years from now)

US10905827 ANTARES PHARMA INC Injection device with cammed ram assembly
Aug, 2031

(8 years from now)

US10821072 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Jun, 2033

(10 years from now)

US10881798 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone
Oct, 2034

(11 years from now)

US10238662 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Feb, 2035

(12 years from now)

US10912782 ANTARES PHARMA INC Needle assisted injection administration of testosterone compositions
Feb, 2035

(12 years from now)

US11191908 ANTARES PHARMA INC Syringe shock absorber for use in an injection device
Oct, 2035

(12 years from now)

US9744302 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Nov, 2035

(12 years from now)

US9950125 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Sep, 2036

(13 years from now)

US10646495 ANTARES PHARMA INC Testosterone ester triglyceride formulations
Aug, 2038

(15 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in